RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis
USA - NASDAQ:RIGL - US7665597024 - Common Stock
29.5 USD
-0.19 (-0.64%)
Overall RIGL gets a fundamental rating of 6 out of 10. We evaluated RIGL against 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. An interesting combination arises when we look at growth and value: RIGL is growing strongly while it also seems undervalued. This makes RIGL very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 47.32%, RIGL belongs to the top of the industry, outperforming 99.63% of the companies in the same industry.
RIGL's Return On Equity of 119.39% is amongst the best of the industry. RIGL outperforms 99.25% of its industry peers.
RIGL has a Return On Invested Capital of 68.80%. This is amongst the best in the industry. RIGL outperforms 99.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 47.32% | ||
| ROE | 119.39% | ||
| ROIC | 68.8% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 36.51%, RIGL belongs to the top of the industry, outperforming 97.00% of the companies in the same industry.
With an excellent Operating Margin value of 39.04%, RIGL belongs to the best of the industry, outperforming 98.50% of the companies in the same industry.
The Gross Margin of RIGL (91.52%) is better than 92.32% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.04% | ||
| PM (TTM) | 36.51% | ||
| GM | 91.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
RIGL has more shares outstanding than it did 1 year ago.
RIGL has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
RIGL has an Altman-Z score of -2.89. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.89, RIGL is in line with its industry, outperforming 45.32% of the companies in the same industry.
RIGL has a debt to FCF ratio of 0.91. This is a very positive value and a sign of high solvency as it would only need 0.91 years to pay back of all of its debts.
RIGL's Debt to FCF ratio of 0.91 is amongst the best of the industry. RIGL outperforms 94.57% of its industry peers.
RIGL has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RIGL (0.46) is worse than 71.91% of its industry peers.
Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 0.91 | ||
| Altman-Z | -2.89 |
ROIC/WACC7.87
WACC8.74%
2.3 Liquidity
A Current Ratio of 2.02 indicates that RIGL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.02, RIGL is doing worse than 74.34% of the companies in the same industry.
RIGL has a Quick Ratio of 1.90. This is a normal value and indicates that RIGL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.90, RIGL is not doing good in the industry: 74.72% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 729.07%, which is quite impressive.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 105.62%.
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)729.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5566.67%
Revenue 1Y (TTM)105.62%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%176.01%
3.2 Future
The Earnings Per Share is expected to grow by 29.86% on average over the next years. This is a very strong growth
RIGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.40% yearly.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.45, the valuation of RIGL can be described as very cheap.
Based on the Price/Earnings ratio, RIGL is valued cheaper than 98.31% of the companies in the same industry.
RIGL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.00.
Based on the Price/Forward Earnings ratio of 7.66, the valuation of RIGL can be described as very cheap.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 98.31% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (22.87), we can say RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 7.66 |
4.2 Price Multiples
RIGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.88% of the companies in the same industry.
98.50% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.04 | ||
| EV/EBITDA | 4.01 |
4.3 Compensation for Growth
RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
RIGL's earnings are expected to grow with 61.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RIGL (10/29/2025, 10:42:35 AM)
29.5
-0.19 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change-0.87%
Ins Owners2.58%
Ins Owner Change1.25%
Market Cap529.23M
Revenue(TTM)267.92M
Net Income(TTM)97.82M
Analysts76.67
Price Target39.1 (32.54%)
Short Float %19.93%
Short Ratio5.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)308.53%
Min EPS beat(2)24.64%
Max EPS beat(2)592.43%
EPS beat(4)4
Avg EPS beat(4)440.39%
Min EPS beat(4)24.64%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)241.24%
EPS beat(12)11
Avg EPS beat(12)177.31%
EPS beat(16)13
Avg EPS beat(16)133.23%
Revenue beat(2)2
Avg Revenue beat(2)15.63%
Min Revenue beat(2)12.08%
Max Revenue beat(2)19.17%
Revenue beat(4)4
Avg Revenue beat(4)17.43%
Min Revenue beat(4)9.15%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)9.33%
Revenue beat(12)10
Avg Revenue beat(12)13.36%
Revenue beat(16)11
Avg Revenue beat(16)9.9%
PT rev (1m)0%
PT rev (3m)13.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)307.02%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 7.66 | ||
| P/S | 1.98 | ||
| P/FCF | 8.04 | ||
| P/OCF | 8.04 | ||
| P/B | 6.46 | ||
| P/tB | 9.45 | ||
| EV/EBITDA | 4.01 |
EPS(TTM)5.41
EY18.34%
EPS(NY)3.85
Fwd EY13.06%
FCF(TTM)3.67
FCFY12.43%
OCF(TTM)3.67
OCFY12.44%
SpS14.93
BVpS4.57
TBVpS3.12
PEG (NY)0.01
PEG (5Y)N/A
Graham Number23.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 47.32% | ||
| ROE | 119.39% | ||
| ROCE | 87.08% | ||
| ROIC | 68.8% | ||
| ROICexc | 704.92% | ||
| ROICexgc | N/A | ||
| OM | 39.04% | ||
| PM (TTM) | 36.51% | ||
| GM | 91.52% | ||
| FCFM | 24.56% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score6
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 0.91 | ||
| Debt/EBITDA | 0.35 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 15.13 | ||
| Cash Conversion | 61.51% | ||
| Profit Quality | 67.26% | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | -2.89 |
F-Score6
WACC8.74%
ROIC/WACC7.87
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)729.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5566.67%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)105.62%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%176.01%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1259.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5YN/A
FCF growth 1Y235.34%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y297.38%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 10 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.